OPL-002 not checked
Vector Y Therapeutics · Oppilan Pharma Ltd · VTX002
FollowEvery change as it happens, and a Monday email
Trials
1 active
3 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “An investigational gene therapy targeting a specific protein.”In the company’s words, NCT07287397 on ClinicalTrials.gov
- Tested for
- Amyotrophic Lateral Sclerosis
- Main trialPhase 1/2
- “PIONEER-ALS is a Phase 1/2, multicenter, open-label, ascending dose, uncontrolled, first-in-human study that will evaluate the safety, tolerability and effects on clinical and biomarker endpoints of intracisternal administration of Vtx-002 in participants with Amyotrophic Lateral Sclerosis (ALS). Two escalating dose (low dose and high dose) cohorts are planned. The duration of the study will be a maximum of 5 years and 5 weeks (265 weeks) for each participant. The screening period may last up to 5 weeks to complete screening procedures.”In the company’s words, NCT07287397 on ClinicalTrials.gov
- Other names
- VTX002
Other drugs for Amyotrophic Lateral Sclerosis
Coming up1
- 15 Oct 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 15 Oct 2027 | Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS | |
| Phase 2Terminated | 30 Aug 2023 | VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis | |
| Phase 1Completed | 24 Feb 2021 | A PK Dose Proportionality Study of OPL-002 in Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026